MAIA Biotechnology, Inc. MAIA 深 沪
等待开盘 06-10 09:30:00 美东时间
1.30
+0.030
+2.36%
华盛通- 最 高1.33
- 今 开1.29
- 成交量 61.21万股
- 最 低 1.26
- 昨 收 1.27
- 总市值 7904.10万
- 52周最高 3.19
- 市盈率 静 --
- 换手率 1.01%
- 52周最低 0.87
- 委 比 -69.82%
- 总股本 6080.08万
- 历史最高 9.64
- 量 比 0.28
- 振 幅 5.51%
- 历史最低 0.82
- 每 手 1
- 风险率 0.33%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多MAIA Biotechnology Insiders Founder/CEO Vlad Vitoc, M.D. And Director Stan V. Smith, Ph.D. Increase Ownership Position Through Open Market Purchases Of ~147,700 Shares Worth ~$201K
Approximately 72,700 shares of MAIA common stock were purchased by Dr. Vitoc on June 6, 2026, at an average common stock price of $1.3877. Approximately 75,000 shares of MAIA common stock were purchased by Dr. Smith on
06-02 21:54
MAIA Biotechnology Q1 EPS $(0.14) Beats $(0.18) Estimate
MAIA Biotechnology (AMEX:MAIA) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.18) by 22.22 percent. This is a 12.5 percent increase over losses of $(0.16) per share from
05-11 21:31
MAIA Biotechnology Activates First Clinical Facility In U.S. In Its Phase 2 THIO-101 Expansion Study To Treat Non-Small Cell Lung Cancer
MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that it has activated the first U.S.
04-16 21:23
MAIA Biotechnology Reports Over 2-Year Survival In Phase 2 THIO-101 NSCLC Trial;
Potential breakthrough therapeutic targets $50B+ global immunotherapy market1CHICAGO, March 31, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical
03-31 21:19
MAIA Biotechnology Q4 EPS $(0.08) Beats $(0.13) Estimate
MAIA Biotechnology (AMEX:MAIA) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.13) by 38.46 percent. This is a 33.33 percent increase over losses of $(0.12) per share from
03-24 06:11
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Edesa Biotech (NASDAQ:EDSA) shares rose 61.0% to $3.67 during Tuesday'...
03-04 01:05
MAIA Biotechnology Highlights Phase 3 Momentum And FDA Fast Track For Ateganosine In Third-Line NSCLC
Ongoing Phase 3 full approval clinical trial of ateganosine holds high probability of technical success for interim and full analysisFDA Fast Track designation offers clear pathway for ateganosine as third-line therapy
02-24 21:47
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Nuwellis (NASDAQ:NUWE) shares rose 81.5% to $3.9 during Tuesday's regu...
01-28 01:05
MAIA Biotechnology Announces Milestones And Growth Catalysts For 2026; Initial Measures Of Efficacy From Phase 3 Study, Conclusion Of Part C Of Phase 2 Study, Engage In Regulatory Interactions With The FDA, Clinical Development Of Second-generation Molecules To Start In Phase 1 Trials
MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today provided a corporate update on 2025 achievements
01-20 23:25
MAIA Biotechnology announces $1.51M private placement
MAIA Biotechnology (NYSE:MAIA) announced on Tuesday that it has entered into definitive agreements for the purchase and sale of an aggregate of 1.23M shares of common stock at a price of $1.224 per s...
2025-12-17 05:33
